ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1111

Transient Elastography (fibroscan); As a New Non-invasive Diagnostic Method for Detecting Hepatic Involvement of Amyloidosis

Murat Bektaş1, Bilger Çavuş2, Besim Fazil Agargun3, Volkan Şenkal2, Nevzat Koca4, Burak Ince4, Pelin Özer Karaca5, Metban Mestanzade6, Melek Büyük7, Melike Zehra Buğra5, Mine Güllüoğlu7, Sevgi Beşışık6, Yasemin Yalcinkaya8, Bahar Esen8, Murat İnanç9, Fatih Beşışık2 and Ahmet Gül10, 1Istanbul Faculty of Medicine, Istanbul, Turkey, 2Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Gastroenterology, İstanbul, Turkey, 3Istanbul Faculty of Medicine, Istanbul University, Department of Internal Medicine, İstanbul, Turkey, 4Istanbul Faculty of Medicine, Istanbul University, Division of Rheumatology, İstanbul, Turkey, 5Istanbul University, Istanbul Faculty of Medicine, Department of Cardiology, İstanbul, Turkey, 6Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Hematology, İstanbul, Turkey, 7Istanbul University, Istanbul Faculty of Medicine, Department of Pathology, İstanbul, Turkey, 8Division of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, 9Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İstanbul, Turkey, 10Division of Rheumatology, Istanbul University Istanbul School of Medicine, Istanbul, Turkey

Meeting: ACR Convergence 2021

Keywords: Amyloidosis, Familial Mediterrenean Fever, Liver stiffness, MEFV variant, transient elastography

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 8, 2021

Title: Miscellaneous Rheumatic & Inflammatory Diseases Poster II: Clinical Features & Diagnostics (1083–1117)

Session Type: Poster Session C

Session Time: 8:30AM-10:30AM

Background/Purpose: Amyloidosis is characterized by accumulation of insoluble fibrils composed of different monomers in extracellular spaces of different organs, and demonstration of deposits by non-invasive methods is important especially for organs difficult to sample. Transient elastography (fibroscan) is a diagnostic method being used to measure liver stiffness (LS) in different chronic liver diseases. We herein aimed to test the place of fibroscan method for detecting increased LS associated with amyloid deposition in patients with amyloidosis.

Methods: Six categories of patients enrolled into this cross-sectional study; AA amyloidosis (AA-a), AL amyloidosis (AL-a), Familial Mediterranean Fever (FMF) patients without amyloidosis, cirrhotic chronic liver disease, non-cirrhotic chronic hepatitis B infection (CHB) and healthy controls (HC). LS assessment by fibroscan were categorized as normal for kPa< 7, significant stiffness for kPa≥7, advanced stiffness for kPa≥9.5 and kPa≥F4 stiffness. FIB-4 and APRI scores were calculated for each patient when they indicated chronic liver disease. Patients with known chronic liver disease and viral hepatitis excluded from amyloidosis and FMF groups.

Results: A total of 165 patients (AA-a, n=65; AL-a, n=15; FMF, n=20; cirrhotic patients, n=16; CHB, n=22; HC, n=27) constituted the study group. Clinical and laboratory features of patients are given in Table 1. Average age was higher in the AL-a group compared to others. Median LS was highest in cirrhotic patients, and it was also higher in AA-a and AL-a patients compared to FMF and HC. Median LS was numerically higher in AL-a compared to AA-a, but it did not reach statistical significance. Median LS was also higher in FMF patients compared to HC. FIB-4 and APRI scores were lower compared to cirrhotic patients in AA-a and AL-a. ALP levels were higher in AA-a and AL-a groups compared to FMF, CHB and HC. FIB-4 and APRI scores, ALP and GGT levels were correlated with LS both in AA-a, AL-a and FMF-AA groups (Table 2). The scores of amyloid depositions were higher in non-FMF-AA-a patients compared to FMF-AA-a. In FMF-AA-a group, median LS, FIB-4 score, GGT, creatinine, cardiac septal wall thickness (CSWT) and frequency of advanced stiffness were higher in patients who had one exon 10 MEFV variant compared to those with two variants. Frequency of advanced and F4 stiffness, GIS involvement and CSWT were lower in M694V homozygous compared to other MEFV variants.
Higher patient age, age at diagnosis of amylodosis, FIB-4 and LS scores, ALP levels, non-FMF causes of AA were associated with hepatic AA amyloid involvement in biopsy-proven patients. A cut-off value 12.05 kPa of LS provided 100% sensitivity and 85.5% specificity (LR=6.9, AUC=0.901, 95% CI 0.81-0.99) for patients with AA-a.

Conclusion: In our single center cohort, we showed a higher median LS by fibroscan in both AL-a and AA-a patients compared to CHB, FMF and HC. Additionally, hepatic amyloid involvement and median LS was higher in non-FMF-AA-a compared to FMF-AA-a, and in FMF-AA-a patients with one exon 10 MEFV variant compared to those with two variants suggesting presence of amyloidogenic genetic factors additional to pathogenic MEFV variants.

Yeni-Microsoft-Word-Belgesi.jpeg”p1: comparison of amyloidosis and FMF patients p2: comparison of amyloidosis and cirrhosis p3: comparison of amyloidosis and chronic liver disease p4: comparison of amyloidosis and healthy control p5: comparison of FMF and healthy control p6: comparison of AA and AL amyloidosis * Mann Whitney U test Ɨ Fischer’s exact test SD: Standard deviation, IQR: Interquartile range, FMF: Familial Mediterranean Fever, kPa: Kilopascal, FIB_4: Fibrosis_4 index, APRI: AST to platelet ratio index, ALT: Alanine aminotransferase, AST: aspartate aminotransferase, ALP: Alkaline phosphatase, GGT: Gama glutamyl transferase

*After exclusion of patients had chronic renal failure SD: Standard deviation, IQR: Interquartile range, FMF: Familial Mediterranean Fever, CRP: C-reactive protein, FIB_4: Fibrosis_4 index, APRI: AST to platelet ratio index, ALT: Alanine aminotransferase, AST: Aspartate aminotransferase, ALP: Alkaline phosphatase, GGT: Gama glutamyl transferase


Disclosures: M. Bektaş, None; B. Çavuş, None; B. Agargun, None; V. Şenkal, None; N. Koca, None; B. Ince, None; P. Özer Karaca, None; M. Mestanzade, None; M. Büyük, None; M. Buğra, None; M. Güllüoğlu, None; S. Beşışık, None; Y. Yalcinkaya, None; B. Esen, None; M. İnanç, None; F. Beşışık, None; A. Gül, None.

To cite this abstract in AMA style:

Bektaş M, Çavuş B, Agargun B, Şenkal V, Koca N, Ince B, Özer Karaca P, Mestanzade M, Büyük M, Buğra M, Güllüoğlu M, Beşışık S, Yalcinkaya Y, Esen B, İnanç M, Beşışık F, Gül A. Transient Elastography (fibroscan); As a New Non-invasive Diagnostic Method for Detecting Hepatic Involvement of Amyloidosis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/transient-elastography-fibroscan-as-a-new-non-invasive-diagnostic-method-for-detecting-hepatic-involvement-of-amyloidosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/transient-elastography-fibroscan-as-a-new-non-invasive-diagnostic-method-for-detecting-hepatic-involvement-of-amyloidosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology